

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 65

Published online February 20, 2023

Online  
Article

IN THIS ISSUE

A Second Indication for Tucatinib (*Tukysa*)

### Important Copyright Message

**FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769**

# The Medical Letter®

## on Drugs and Therapeutics

Volume 65

Published online February 20, 2023

Online  
Article

### IN THIS ISSUE

#### A Second Indication for Tucatinib (*Tukysa*)

### IN BRIEF

#### A Second Indication for Tucatinib (*Tukysa*)

The oral kinase inhibitor tucatinib (*Tukysa* – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (*Herceptin*) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine (*Xeloda*, and generics) for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who received at least one prior anti-HER2-based regimen for metastatic disease.<sup>1</sup>

**MECHANISM OF ACTION** – Tucatinib binds irreversibly to HER2 and other enzymes that promote cell growth, resulting in reduced signaling, cell cycle arrest, and apoptosis. Tucatinib penetrates the blood-brain barrier more effectively than anti-HER2 monoclonal antibodies, which may allow for more effective treatment of brain metastases.<sup>2</sup>

**CLINICAL STUDIES** – Accelerated approval of tucatinib was based on the results of an unpublished (summarized in the package insert), open-label trial (MOUNTAINEER) in 84 patients with HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer who received prior treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody. Patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) disease also had to receive prior treatment with an anti-programmed cell death protein-1 (PD-1) monoclonal antibody. Patients who

received prior anti-HER2 therapy were excluded. All patients received tucatinib 300 mg twice daily with trastuzumab (8 mg/kg IV on day 1 of cycle 1, then 6 mg/kg on day 1 of each subsequent 21-day cycle) until disease progression or unacceptable toxicity occurred. The overall response rate (ORR) was 38%, of which 3% were complete responses. The median duration of response was 12.4 months and 81% of patients had a duration of response  $\geq 6$  months and 34% had a duration of response  $\geq 12$  months.

**ADVERSE EFFECTS** – The most common adverse effects (frequency  $\geq 20\%$ ) of tucatinib in the MOUNTAINEER trial were diarrhea, fatigue, rash, nausea, abdominal pain, infusion-related reactions, and pyrexia. Severe hepatotoxicity can occur; transaminase and bilirubin levels should be monitored before starting tucatinib and every 3 weeks during treatment.

**DRUG INTERACTIONS** – Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent by CYP3A. It should not be used concurrently with strong CYP3A inducers, moderate CYP2C8 inducers, or strong CYP2C8 inhibitors. If coadministration of a strong CYP2C8 inhibitor is necessary, the dosage of tucatinib should be reduced to 100 mg twice daily. Tucatinib is an inhibitor of CYP3A and P-glycoprotein (P-gp) and a substrate of P-gp; concurrent use of tucatinib with a P-gp or CYP3A substrate can increase serum concentrations of the substrate and possibly its toxicity.<sup>3</sup>

**PREGNANCY AND LACTATION** – In animal studies, tucatinib was associated with fetal death, decreased fetal weight, and fetal abnormalities at exposures 3.5 times the human exposure at the recommended dose. Women of reproductive potential and their male partners should use effective contraception during tucatinib treatment and for at least 1 week after

the last dose. There are no data on the presence of tucatinib in human breast milk or on its effect on the breastfed infant or milk production. Women should not breastfeed during treatment with tucatinib and for at least 1 week after the last dose.

**DOSAGE, ADMINISTRATION, AND COST** –Tucatinib is available in 50- and 150-mg tablets. The recommended dosage for the new indication is 300 mg taken every 12 hours in combination with trastuzumab until disease progression or unacceptable toxicity occurs. The tablets should be swallowed whole and not be crushed, chewed, or split. A missed dose should be skipped, and the next dose should be taken at its regularly scheduled time. The dosage should be reduced to 200 mg twice daily in those with severe hepatic impairment (Child-Pugh C). The labeling

specifies a number of dosage adjustments that should be made if adverse effects occur. A 30-day supply of *Tukysa* costs \$23,514.<sup>4</sup> ■

1. Two drugs for advanced HER2-positive breast cancer. *Med Lett Drugs Ther* 2020; 62:182.
2. R Duchnowska et al. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. *Cancer Treat Rev* 2018; 67:71.
3. Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. *Med Lett Drugs Ther* 2023 January 25 (epub). Available at: [medicalletter.org/downloads/CYP\\_PGP\\_Tables.pdf](http://medicalletter.org/downloads/CYP_PGP_Tables.pdf)
4. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: *AnalySource@Monthly*, February 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. [www.fdbhealth.com/policies/drug-pricing-policy](http://www.fdbhealth.com/policies/drug-pricing-policy).

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
[www.medicalletter.org](http://www.medicalletter.org)

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.